Julia Holle Selected Research

Antineutrophil Cytoplasmic Antibodies (ANCA)

5/2022	[Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
1/2017	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.
11/2012	Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
5/2011	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
12/2009	Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides.
2/2004	Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julia Holle Research Topics

Disease

6	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2023 - 12/2009
6	Vasculitis (Vasculitides) 05/2022 - 12/2009
3	Infections 01/2023 - 12/2009
3	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2017 - 02/2004
2	Giant Cell Arteritis (Horton Disease) 01/2018 - 01/2017
2	Microscopic Polyangiitis 01/2017 - 12/2009
2	Churg-Strauss Syndrome (Allergic Angiitis) 01/2017 - 12/2009
2	Rheumatoid Arthritis 05/2011 - 02/2004
2	Inflammation (Inflammations) 12/2009 - 05/2008
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2023
1	Neoplasms (Cancer) 01/2023
1	Systemic Scleroderma (Systemic Sclerosis) 01/2018
1	Rheumatic Diseases (Rheumatism) 01/2017
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2011
1	Pemphigus (Pemphigus Vulgaris) 05/2011
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2011
1	Autoimmune Diseases (Autoimmune Disease) 05/2011
1	Multiple Sclerosis 05/2011
1	Systemic Vasculitis 12/2009
1	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2002

Drug/Important Bio-Agent (IBA)

6	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 05/2022 - 02/2004
5	Rituximab (Mabthera)FDA Link 01/2023 - 05/2011
2	CytokinesIBA 01/2018 - 12/2009
1	Immunoglobulin G (IgG)IBA 01/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	GlucocorticoidsIBA 01/2023
1	Prednisone (Sone)FDA LinkGeneric 01/2023
1	avacopanIBA 01/2021
1	PlasminogenIBA 01/2017
1	Edetic Acid (EDTA)FDA Link 01/2017
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2017
1	Methotrexate (Mexate)FDA LinkGeneric 01/2017
1	Prostaglandins AIBA 05/2011
1	Immunologic Factors (Immunomodulators)IBA 12/2009
1	Proteinase-Activated ReceptorsIBA 12/2009
1	Interleukin-15 (Interleukin 15)IBA 05/2008
1	Myeloblastin (Proteinase 3)IBA 02/2004
1	N 30IBA 02/2004

Therapy/Procedure

2	Therapeutics 11/2012 - 05/2011
1	Remission Induction 01/2017
1	Transplantation 02/2002